Organization · Venture Capital
Arsenal Bridge Ventures
Arsenal Bridge Ventures is an early-stage venture capital firm based in Austin, Texas, focusing on biotechnology innovations from mid-continent research universities. The firm aims to leverage less saturated markets to create value from elite scientific advancements.
Overview
What Arsenal Bridge Ventures does
What Arsenal Bridge Ventures is
Arsenal Bridge Ventures is an early-stage venture capital firm based in Austin, Texas, focusing on biotechnology innovations from mid-continent research universities. The firm aims to leverage less saturated markets to create value from elite scientific advancements.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- March 27, 2026
Official channels
Find Arsenal Bridge Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Arsenal Bridge Ventures as a funder
Investment thesis
Arsenal Bridge Ventures focuses on advancing biotechnology innovations from mid-continent research universities, leveraging less saturated markets to source high-impact deals.
Focus narrative
The firm invests in high-impact biotechnology innovations, employing strategies such as leadership recruitment, capital deployment, and syndication to optimize asset value. Arsenal Bridge Ventures targets markets that are less crowded than traditional biotech hubs, focusing on the unique opportunities presented by mid-continent research institutions.
Value beyond capital
Arsenal Bridge Ventures adds value to its portfolio companies through strategic leadership recruitment, capital deployment, and leveraging the extensive networks of its partners, including industry leaders like Reid Hoffman and Clay B. Siegall.
Terms and economics
- Typical check
- $7,800,000
Focus and fit
- Stages
- Seed · Series A · Series B
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
- Recorded notable exits
- Seagen
Portfolio context
Notable portfolio companies include Tetricus, Eradivir (antiviral biotech), MorphImmune (NASDAQ: IMNM), Novosteo (NASDAQ: QNCX), Courage Therapeutics (a University of Michigan spinout focused on obesity and eating disorders), Valerion Energy (energy/biotech intersection), and Qana Therapeutics.
Common questions
What to know about Arsenal Bridge Ventures
Upseed classifies Arsenal Bridge Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.